Pharma BD Deal Intelligence
A $5.76B licensing deal that made Monte Rosa's molecular glue degrader platform the backbone of Novartis's second immunology collaboration, with just $120M upfront against up to $5.4B in milestones. The heavy back-loading leaves Monte Rosa's near-term economics thin despite the platform validation.
Novartis gains an exclusive license to an undisclosed Monte Rosa discovery-stage target as well as options to license two programs from Monte Rosa's…
Novartis announced a licensing agreement with Monte Rosa Therapeutics valued upwards of $5.7 billion that aims at developing drugs for immune-mediated…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Novartis pledged up to $5.76B to Monte Rosa Therapeutics in its second molecular glue degrader collaboration, announced September 15, 2025, to develop degraders for immune-mediated diseases using Monte Rosa's QuEEN discovery engine. The deal covers an exclusive license to one undisclosed I&I target plus options on two additional preclinical immunology programs. Monte Rosa received a $120M non-refundable upfront in September 2025 (transaction price at inception of $180M including $60M of option-maintenance payments), and is eligible for up to $5.4B in development, regulatory, and sales milestones plus tiered royalties (high single- to low double-digit). The agreement is effective; the upfront was received and is being recognized under ASC 606 per Monte Rosa's Q3 2025 results.
Immune-mediated diseases (spanning rheumatoid arthritis, psoriasis, atopic dermatitis, IBD, multiple sclerosis, hidradenitis suppurativa) is an ~$80B+ biologics market that MRT-6160 (VAV1 molecular glue degrader, T+B cell modulation) enters against multiple entrenched MOA classes. Anti-TNF biologics: adalimumab (Humira, AbbVie; ~$14.4B 2023 global despite biosimilars), etanercept (Enbrel, Amgen), infliximab (Remicade, J&J) plus biosimilars. Anti-IL-17/23: secukinumab (Cosentyx, Novartis; ~$5.3B 2023), ixekizumab (Taltz, Lilly), ustekinumab (Stelara, J&J; ~$10.9B 2023), risankizumab (Skyrizi, AbbVie; ~$7.8B 2023), and guselkumab (Tremfya, J&J). JAK inhibitors: upadacitinib (Rinvoq, AbbVie; ~$4.0B 2023), tofacitinib (Xeljanz, Pfizer), baricitinib (Olumiant, Lilly). Anti-IL-4/13: dupilumab (Dupixent, Regeneron/Sanofi; ~$11.6B 2023). Emerging molecular glue degraders (direct class): MRT-2359 (Monte Rosa, GSPT1 in oncology), CFT1946 (C4 Therapeutics, BRAF), and BMS/Plexium/Nurix/Arvinas targeted protein degrader pipelines - no approved molecular glue for immunology yet. VAV1 is an unprecedented immunology target; MRT-6160 is first-in-class in Phase 1. For Novartis, the commercial threat is the breadth and entrenchment of biologic/oral competition rather than direct VAV1 rivals; differentiation will require clean oral PK and class-differentiated efficacy signals.
Novartis pledged up to $5.76B to Monte Rosa Therapeutics to develop novel molecular glue degraders for immune-mediated diseases. Monte Rosa received $120M upfront, up to $60M in option fees, $180M in preclinical milestones, and up to $5.4B in development, regulatory, and commercial milestones, plus
Collaboration is effective: Monte Rosa received the $120M non-refundable upfront from Novartis in September 2025 (transaction price at inception $180M incl. $60M option maintenance), recognized under ASC 606 per Q3 2025 results. No closing condition / HSR clearance was disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Monte Rosa Therapeutics Inc. (this deal) | 2025 | $5.8B | 58 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2025 deals · Novartis AG deals · Immunology deals